Becton Dickinson and Co (BDX) : St. Johns Investment Management Company reduced its stake in Becton Dickinson and Co by 3.84% during the most recent quarter end. The investment management company now holds a total of 6,236 shares of Becton Dickinson and Co which is valued at $1,096,164 after selling 249 shares in Becton Dickinson and Co , the firm said in a disclosure report filed with the SEC on Jul 19, 2016.Becton Dickinson and Co makes up approximately 0.96% of St. Johns Investment Management Company’s portfolio.
Other Hedge Funds, Including , Charter Trust Co reduced its stake in BDX by selling 1,420 shares or 8.61% in the most recent quarter. The Hedge Fund company now holds 15,064 shares of BDX which is valued at $2,647,950. Becton Dickinson and Co makes up approx 0.30% of Charter Trust Co’s portfolio.Somerset Trust Co boosted its stake in BDX in the latest quarter, The investment management firm added 308 additional shares and now holds a total of 9,781 shares of Becton Dickinson and Co which is valued at $1,720,869. Becton Dickinson and Co makes up approx 1.03% of Somerset Trust Co’s portfolio.Gillespie Robinson Grimm Inc reduced its stake in BDX by selling 12,892 shares or 8.3% in the most recent quarter. The Hedge Fund company now holds 142,390 shares of BDX which is valued at $25,052,097. Becton Dickinson and Co makes up approx 3.90% of Gillespie Robinson Grimm Inc’s portfolio.Capstone Asset Management Co boosted its stake in BDX in the latest quarter, The investment management firm added 1,383 additional shares and now holds a total of 24,592 shares of Becton Dickinson and Co which is valued at $4,326,716. Becton Dickinson and Co makes up approx 0.13% of Capstone Asset Management Co’s portfolio.
Becton Dickinson and Co opened for trading at $175.19 and hit $176.33 on the upside on Wednesday, eventually ending the session at $175.78, with a gain of 0.72% or 1.26 points. The heightened volatility saw the trading volume jump to 5,08,577 shares. Company has a market cap of $37,301 M.
On the company’s financial health, Becton Dickinson and Co reported $2.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.01. The company had revenue of $3067.00 million for the quarter, compared to analysts expectations of $3073.41 million. The company’s revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Reiterated by RBC Capital Mkts on May 9, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 169 from a previous price target of $153 .
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.